Early Investor Incentive – Clinical Catalyst Bonus

Investments within the first $250,000 of the offering are eligible for a 10% Principal Bonus. Eligible investors will have their investment principal increased by 10% for purposes of conversion (for example, a $1,000 investment converts as $1,100). This incentive is available on a first-funded basis while the Tier 1 allocation remains available and is subject to the terms of the Form C.

Raised to Date
$632,500*

Invest Now
ID:
ZG-CF-2025
Exemption:
REG-CF
Issue Type:
Convertible Note
Accredited Only:
No
Financials:
Reviewed
Reviewed By:
SetApart Accountancy Corp
Price per Note:
$1.00
Minimum Investment:
$1,000
Requested Investment:
$5,000
Investment Increments:
$500
Minimum Goal:
$50,000
Stretch Goal:
$250,000
Maximum Goal:
$1,235,000
Raise Start Date:
March 31st, 2026
Raise Target Date:
April 1st, 2026
Raise End Date:
January 31st, 2027
* Previously Raised:
$632,500
 
Zephyr Group - Business Plan
 
Zephyr Group - Reviewed Financial Statements
 
Zephyr Group - Bylaws
 
Zephyr Group - Subscription Agreement
SEC EDGAR Filings: 
Investment Disclosures

Investor Forum

Send me campaign updates 

Zephyr Group, Inc.: Investing in the Future of Healthspan

Bridging the Gap Between Nature and Modern Bioscience

The Core Thesis: "Life to Years"

Zephyr Group, Inc. is an emerging biotechnology company dedicated to healthspan optimization. We are moving beyond the "reactive" healthcare model to develop evidence-based solutions at the intersection of therapeutic peptides, high-potency phytoceuticals, and advanced delivery systems.

The Zephyr Identity: Precision. Longevity. Patented.

The Problem: A Reactive Healthcare Crisis

Modern medicine is designed for late-stage intervention. We treat chronic conditions after they appear, rather than addressing the root causes of aging and metabolic decline. Furthermore, the "natural" supplement market is plagued by:

  • Bioavailability Gaps: Active compounds that are poorly absorbed by the body.
  • Transparency Void: Lack of consistent quality and scientific rigor.
  • Scientific Stagnation: Products that fail to evolve alongside modern biotechnology.

The Solution: The Zephyr Convergence Platform

Zephyr bridges the gap between nature-based compounds and pharmaceutical-grade science. Our platform-first strategy ensures that every product is:

  1. Synergistic: Pairing signaling peptides with plant-derived actives for multi-target efficacy.
  2. Highly Bioavailable: Utilizing liposomal and exosomal delivery to ensure compounds reach their cellular targets.
  3. Validated: A rigorous commitment to clinical data and quality control.

Product Pipeline: Targeting the Metabolic Revolution

With the global shift toward metabolic health and GLP-1 awareness, Zephyr is positioned with high-demand assets:

Asset

Target

Status

Z-Metabolic Lead

Type II Diabetes/Blood Glucose

Positive early data on HbA1c & lipids

Z-GLP-1 Natural

Satiety & Weight Management

Market-ready formulation

Next-Gen Delivery

Nutrient/Peptide Absorption

In development (Exosomal focus)

Why Now? Converging Tailwinds

We are at the "Golden Age" of longevity science. Investors are increasingly looking for alternatives to traditional pharma that offer:

  • Preventative Focus: A massive shift toward personalized wellness.
  • Metabolic Awareness: Global demand for weight-management and glucose-stability solutions.
  • Validated Innovation: The rise of "Science-Backed Wellness" as a distinct, high-growth asset class.



Use of Proceeds: From Foundation to Acceleration

This Reg-CF offering is a strategic step to fuel our disciplined growth.

At Minimum Target:

  • Regulatory Compliance: Solidifying our legal and financial foundations.
  • Investor Relations: Scaling communications and transparency.
  • Foundational Marketing: Building the brand architecture for commercial launch.

At Maximum Target:

  • Reg A+ Preparation: Setting the stage for a larger institutional-grade raise.
  • Accelerated Commercialization: Rapidly bringing our GLP-1 and Metabolic assets to market.
  • M&A Evaluation: Identifying strategic acquisitions to expand our IP portfolio.

Rooted in Conviction

Founded in 2021, Zephyr Group was born from a personal realization: Prevention is the only sustainable path. Our leadership team combines healthcare experience with a relentless focus on integrity and accountability. We aren't just building products; we are building a standard for the longevity industry.

Early Investor Incentive – Clinical Catalyst Bonus

To recognize early supporters of the offering, the Company is offering a Tier 1 Early Investment Incentive referred to as the Clinical Catalyst Principal Bonus.

Eligibility - Investors whose investments are funded and cleared within the first $250,000 of accepted investments in this offering will be eligible for the incentive, on a first-funded basis.

Incentive Terms - Eligible investors will receive a 10% Principal Bonus, meaning that the principal amount of their investment will be increased by 10% solely for purposes of calculating the number of securities issued upon conversion.

Example - An investor who invests $1,000 and qualifies for the incentive will have their investment recorded as a $1,100 principal amount for purposes of conversion into securities under the terms of the Note.

Important Notes

  • The Principal Bonus applies only to investments that are accepted and funded while the first $250,000 incentive allocation remains available.

  • Once the Tier 1 allocation is fully subscribed, subsequent investors will not receive this incentive.

  • The bonus increases the conversion principal amount only and does not represent additional cash proceeds paid by the investor.

  • All incentives are subject to the terms described in the Form C.

Join the Mission.

Review our full offering details and risk factors on the campaign page to see if your vision for the future of health aligns with ours.